Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 2
1953 1
1961 5
1962 1
1963 1
1965 3
1966 8
1967 1
1968 2
1969 4
1970 5
1972 2
1973 4
1974 1
1975 1
1976 3
1977 1
1978 2
1979 1
1981 2
1982 1
1984 2
1985 1
1986 3
1987 2
1989 2
1990 2
1992 2
1993 1
1997 2
2000 2
2002 1
2004 2
2005 2
2006 1
2007 1
2008 3
2009 1
2010 2
2011 2
2012 1
2013 2
2014 3
2015 3
2016 2
2017 3
2018 3
2019 5
2020 2
2021 2
2022 2
2023 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

109 results

Results by year

Filters applied: . Clear all
Page 1
Preservation of Axillary Lymph Nodes Compared with Complete Dissection in T1-2 Breast Cancer Patients Presenting One or Two Metastatic Sentinel Lymph Nodes: The SINODAR-ONE Multicenter Randomized Clinical Trial.
Tinterri C, Gentile D, Gatzemeier W, Sagona A, Barbieri E, Testori A, Errico V, Bottini A, Marrazzo E, Dani C, Dozin B, Boni L, Bruzzi P, Fernandes B, Franceschini D, Spoto R, Torrisi R, Scorsetti M, Santoro A, Canavese G; SINODAR-ONE Collaborative Group. Tinterri C, et al. Ann Surg Oncol. 2022 Sep;29(9):5732-5744. doi: 10.1245/s10434-022-11866-w. Epub 2022 May 12. Ann Surg Oncol. 2022. PMID: 35552930 Clinical Trial.
Sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer patients undergoing mastectomy with one to two metastatic sentinel lymph nodes: sub-analysis of the SINODAR-ONE multicentre randomized clinical trial and reopening of enrolment.
Tinterri C, Canavese G, Gatzemeier W, Barbieri E, Bottini A, Sagona A, Caraceni G, Testori A, Di Maria Grimaldi S, Dani C, Boni L, Bruzzi P, Fernandes B, Scorsetti M, Zambelli A, Gentile D; SINODAR-ONE Collaborative Group. Tinterri C, et al. Br J Surg. 2023 Aug 11;110(9):1143-1152. doi: 10.1093/bjs/znad215. Br J Surg. 2023. PMID: 37471574 Free PMC article. Clinical Trial.
Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research.
Zambonin V, De Toma A, Carbognin L, Nortilli R, Fiorio E, Parolin V, Pilotto S, Cuppone F, Pellini F, Lombardi D, Pollini GP, Tortora G, Bria E. Zambonin V, et al. Among authors: pollini gp. Expert Opin Biol Ther. 2017 Apr;17(4):497-506. doi: 10.1080/14712598.2017.1289171. Epub 2017 Feb 13. Expert Opin Biol Ther. 2017. PMID: 28133971 Review.
Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: sensitivity analysis of randomized trials.
Carbognin L, Sperduti I, Nortilli R, Brunelli M, Vicentini C, Pellini F, Pollini GP, Giannarelli D, Tortora G, Bria E. Carbognin L, et al. Among authors: pollini gp. Cancer Treat Rev. 2015 Mar;41(3):262-70. doi: 10.1016/j.ctrv.2015.02.003. Epub 2015 Feb 9. Cancer Treat Rev. 2015. PMID: 25683304 Review.
Arecoline tripeptide inhibitors of proteasome.
Marastoni M, Baldisserotto A, Canella A, Gavioli R, Risi CD, Pollini GP, Tomatis R. Marastoni M, et al. Among authors: pollini gp. J Med Chem. 2004 Mar 11;47(6):1587-90. doi: 10.1021/jm0309102. J Med Chem. 2004. PMID: 14998343
109 results